Plamotamab  (Synonyms: XmAb-13676)

Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20⁺ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo^[1][2].

Plamotamab induces the killing of endogenous B cells and activation of endogenous CD8⁺ T cells within human PBMCs in vitro, with an EC₅₀ value of 0.113 nM^[2].
Plamotamab induces T cell-mediated killing in Raji tumor cells in vitro, with an EC₅₀ value of 0.144 nM^[2].
Plamotamab binds to CD3δ/ε, CD3⁺ T cells, CD4⁺ T cells, CD8⁺ T cells, B cells, Raji cells, with EC₅₀s of 2.1 nM, 11.78 nM, 10.12 nM, 200.3 nM, and 134.8 nM, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Plamotamab (0.17 mg/kg; i.p.) causes tumor growth suppression in human PBMC-engrafted mouse model containing Raji xenograft^[2].
Plamotamab (0.3 mg/kg; i.p.) leads to cytokine release in cynomolgus monkeys, indicating a safety to be improved^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2138442-31-4

Liquid

Colorless to light yellow

[plamotamab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Parrondo RD, et al. Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.  [Content Brief]

  [2]. Luo Peter PZ, et al. Anti-CD3 antibodies and methods of use thereof. World Intellectual Property Organization, WO2022170740 A1. 2022-08-18.